Intellia Therapeutics NTLA EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's EPS (diluted)?
- Intellia Therapeutics (NTLA) reported EPS (diluted) of -$0.81 in Q1 2026.
- How has Intellia Therapeutics's EPS (diluted) changed year-over-year?
- Intellia Therapeutics's EPS (diluted) increased by 26.4% year-over-year, from -$1.10 to -$0.81.
- What is the long-term trend for Intellia Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Intellia Therapeutics's EPS (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from -$3.77 to -$3.82.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.